An interventional study of indirect calorimetry in Juvenile Idiopathic Arthritis, Diabetes and Inflammatory Bowel Disease, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Prevention
Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C…PubMed 33897473 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.
Among the 71 studies in Arthritis, Juvenile with a site in France, this one has the largest planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2019, is one of 13 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 41st registered.
367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 2–16
Alfasigma S.p.A. · Sites in France, Belgium, Czechia and 6 more countries
Ages 8–18
Alfasigma S.p.A. · Sites in France, Germany, United Kingdom
Ages 8–18
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Canada and 5 more countries
Ages 1+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 28
First in 2000; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 61 across the 50 interventional studies, 274 across the 21 observational. Of the 42 that completed or were terminated, 16 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 71 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 6 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
5 of the studies in Arthritis, Juvenile with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
| NCT05927454Institut National de la Santé Et de la Recherche Médicale, FranceAcostill ( RaDiCo Cohort) (RaDiCo Acostill) | 2027-07 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT07634354CHU de ReimsSarcopenia and Juvenile Idiopathic Arthritis | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Arthritis, Juvenile with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the present project is to assess the effects of the chronic diseases and their associated treatments chronic paediatric diseases (CPD), to further understand their impact on physical fitness for public health perspectives. This is an innovative approach in the treatment of chronic paediatric diseases . This project should yield results that help improving treatments for children and adolescents with chronic paediatric diseases throughout physical activity as therapy, reduced pain, fatigue and inflammation, and improvement in physical fitness and life quality. The originality and novelty of this project is to combine architectural, functional and metabolic components of skeletal muscle to further understand the impact of chronic paediatric diseases as a function of treatment, disease activity and maturation status (prepubertal, pubertal or post pubertal).
This study will aim at assessing muscular function (force production capacity and fatigability) in specific or ecologic situations so as to get information about muscle functioning on isolated muscle group (here knee extensors) or during whole body exercise. Moreover, results arising from muscle architecture or quality will allow understanding the decrease in strength or endurance reported in the literature. The data collected will allow us to further understand the impact of the disease on structural, functional and metabolic parameters. Finally, the understanding of these alterations will provide information enabling to establish recommendations in physical activity (PA) to reduce or even counter the effect of the chronic inflammation and prevent at long-term overweight and cardiovascular risks.
The long-term objective is to contribute establishing recommendations or guidelines for prescribing physical activity during medical therapy. Values obtained in pathological children will be compared to those of control children matched for gender and maturation.
Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
Patients will perform physical tests to provide information about their physical fitness (body composition, metabolic flexibility, muscle strength and fatigue, bone mineral density), which will be compared to age- and gender-matched healthy controls. Patients will also complete blood tests to provide information about their inflammatory state to best understand physiological disorders and allow a better classification of the disease status.
Metabolic flexibility assessment
After sitting quietly for 20 min, subjects will perform a graded exercise test to volitional fatigue on an electromagnetically braked cycle ergometer with continuous gas collection and heart rate monitoring. In all subjects, when the Respiratory Exchange Ratio will be ≥1.00, indicating zero fat oxidation, the work rate will be increased by the same increments at 1-min intervals until volitional fatigue. O2 consumption (VO2) peak will be considered maximal when the Respiratory Exchange Ratio will be ≥1.05 and the subject will achieve his age-predicted maximal heart rate [heart rate maximum: (220 - age)]. Indirect calorimetry, as will be used in this study, is the standard method to quantify substrate oxidation rates at rest and during exercise. O2 consumption (VO2) and CO2 production (VCO2) will be averaged over the final 1 min of each work rate, and the results of this test will be used to calculate fat oxidation over a wide range of exercise intensities for each subject with the equations:
Lipids (mg.min-1) = 1.6946 x VO2 - 1.7012 x VCO2 and CHO (mg.min-1) = 4.585 VCO2 - 3.2255 VO2.
Muscle function
o Vertical jump height: Subjects will have to perform a series of vertical jumps. Subjects will perform two squat jumps (SJ) and two counter movements jumps (CMJ) using an OptoJump following standardised guidelines. For SJ, subjects will have to flex their knee at 90° with the hand on the hip to avoid any counter movements induced by the upper limbs. Subjects will have to maintain the position for 3-s. The guidelines for CMJ will be similar, but without short break between standing and flexing positions. For both exercises, subjects will have to jump as high as possible. Vertical jump height will be calculated according the formula where T is time flight duration and g the acceleration of 9.81 m.s-2 of gravity.
o Maximal voluntary strength: Subjects will sit on an isokinetic dynamometer with a hip angle of 40° (0°= standing position). Upper body will be strapped on the chair back and subjects will have to grip the chair to avoid any counter-movements. Their right ankle will be strapped and connected to a force sensor. After a standardised warm up consisting of repeating isometric contractions at increasing intensities, patients will have to perform maximal voluntary isometric contractions (MVIC). MVIC will be performed at different randomized joint angles (29°, 66°, 76°, 87° and 103° [0° = full extension]) to determine the optimal angle producing maximal strength. Two measurements will be performed at each angle to check the reproducibility. A third trial will be performed if the difference between both measurements is higher than 5%. Subjects will be vigorously encouraged to produce maximal voluntary strength during isometric contractions. Root Mean Square (RMS) values will be calculated from the electromyographic (EMG) activity recorded on VL, VM and RF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with juvenile idiopathic arthritis, type 1 diabete mellitus, inflammatory bowel diseases, anorexia nervosa, cancer survivor
Other: indirect calorimetry
healthy children sex- and age-matched
Other: indirect calorimetry
Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
Maximal lipid oxidation rate during submaximal incremental exercise
Percentage variation of the maximal strength rate during isometric contraction between pathological and healthy children
Time frame: at first test (at day 1)
Maximal strength during isometric contraction
Percentage variation of the maximal strength rate during isometric contraction between pathological and healthy children
Time frame: at day 1
Muscle architecture
muscle cross sectional area (mm2) evaluated by peripheral Quantitative Computed Tomography (pQCT)
Time frame: At 6 months
Body composition
fat mass (g.cm²) evaluated by Dual-energy X-ray absorptiometry
Time frame: At 6 months
Maximal muscular strength
maximal strength of knee extensors
Time frame: At day 1
Muscular fatigue
Percentage variation of time to task failure duration during isometric contraction between pathological and healthy children.
Time frame: at 6 months
Blood sample IL-17
blood level of inflammation markers (IL-17)
Time frame: At day 1
Blood sample CRP
blood level of inflammation markers (CRP)
Time frame: At day 1
Blood sample IL-6
blood level of inflammation markers (IL-6)
Time frame: At day 1
Blood sample TNF - a
blood level of inflammation markers (TNF - a)
Time frame: At day 1
Blood sample IL-10
blood level of inflammation markers (IL-10a)
Time frame: At day 1
Blood sample INF
blood level of inflammation markers (INF)
Time frame: At day 1
Blood sample calprotectin
blood level of inflammation markers (calprotectin)
Time frame: At day 1
Started May 2019 (actual). Primary completion is estimated for Dec 2028, 115 months after the start.
Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 115 months is above that.
Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C…PubMed 33897473 ↗
Fel S, Rochette E, Walther G, Echaubard S, Pereira B, Merlin E, Terral D, Duche P. Maximal Fat Oxidation During Exercise Is Already Impaired in Pre-pubescent C…PubMed 33897473 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →